Know where to play. Know how to win. Know before you invest.
Vernon Row helps diagnostics and MedTech companies evaluate, design and execute U.S. commercialization strategies — from market opportunity and reimbursement through pricing, channel strategy and launch.
The U.S. market is more than a market-size calculation.
A large addressable market does not automatically create a viable commercial opportunity.
Success depends on how the product fits into U.S. clinical workflows, how reimbursement and customer economics affect adoption, how frequently the product will be used, how competitors are positioned, and what commercial infrastructure is required to reach the market.
Vernon Row connects those pieces before companies commit significant resources to commercialization.
Data identifies the market. Vernon Row determines how to commercialize it.
U.S. Commercial Readiness Assessment
A focused commercial assessment designed for companies evaluating a U.S. launch, preparing for commercialization, raising capital, or reassessing an existing market strategy.
The flagship Vernon Row engagement.
Discuss a Commercial Readiness AssessmentThe output is not another market report. It is a commercial decision framework and execution roadmap.
Market & Customer Opportunity
Where the real opportunity sits — by customer segment, site of care and geography — and whether it is large enough to justify the investment.
Reimbursement & Economics
How U.S. payment and reimbursement pathways affect adoption, what the customer can economically justify, and where the economics create barriers or opportunities.
Positioning & Business Model
How the product should be positioned, priced and offered commercially—and which business model best supports adoption.
Route to Market
Whether to build a direct U.S. presence, work through distributors or strategic partners, or use a hybrid model—and which customers and regions to prioritize first.
Commercial Roadmap
The organization, sequencing and milestones required to enter the market and build early commercial traction.
Five areas. One commercial decision.
Diagnostics and MedTech companies facing a U.S. commercial decision.
Emerging Diagnostics & MedTech Companies
Companies approaching commercialization that need to validate the commercial opportunity before building significant infrastructure.
International Companies Entering the U.S.
Companies with established technology or products outside the United States that need to understand how the U.S. reimbursement, customer and commercial environment changes their business model.
Investors & Private Equity
Investors evaluating the commercial assumptions behind a diagnostics or MedTech opportunity — commercial due diligence rather than traditional financial diligence.
Established Companies
Companies evaluating new products, indications, customer segments, channels or commercialization strategies.
Built for the economics of diagnostics.
Diagnostics commercialization has a different economic model from traditional medical devices.
Success depends not only on instrument placement, but on test utilization, menu, workflow, reimbursement, customer economics and recurring consumable revenue.
The Complete Diagnostic Commercial Model
Areas of Focus
- Molecular diagnostics
- Point-of-care testing
- Clinical laboratory testing
- Decentralized testing
- Sample preparation
- Diagnostic platforms and consumables
Analysis in service of the commercial decision.
Vernon Row integrates public and commercial healthcare data, reimbursement intelligence, competitive research, client information and AI-enabled analysis to develop commercialization strategies.
The purpose of the analytics is not simply to describe the market.
The Questions the Analysis Answers
- Where should we compete?
- Which customers should we target?
- What commercial model works?
- What should we charge?
- What resources will commercialization require?
- What is the realistic revenue opportunity?
- Should we enter the market?
Turn U.S. market complexity into a commercial plan you can execute.
A focused conversation can clarify where the opportunity is strongest, which commercial model fits, and what should be validated before significant capital is committed.
Assess Your U.S. Opportunity